Enlivex (ENLV) Shares Outstanding (2013 - 2025)
Enlivex (ENLV) posted quarterly Shares Outstanding (Entity) of $3.0 million for Q4 2025, up 93.21% year-over-year from $1.6 million in Q4 2024, and up 90.04% quarter-over-quarter from $1.6 million in Q3 2025.
Enlivex (ENLV) Shares Outstanding (2013 - 2025) Analysis & Trends
Enlivex's Shares Outstanding (Entity) history runs 13 years deep, the most recent figure standing at $3.0 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 93.21% year-over-year to $3.0 million; the TTM figure through Dec 2025 stood at $3.0 million (up 93.21% YoY), while the FY2025 annual figure was $3.0 million, up 93.21% from the prior year.
- Shares Outstanding (Entity) for Q4 2025 stood at $3.0 million, up from $1.6 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $3.0 million in Q4 2025, with the low at $1.2 million in Q1 2021.
- The 5-year median for Shares Outstanding (Entity) is $1.2 million (2023), against an average of $1.4 million.
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) grew 0.37% in 2022, then soared 93.21% in 2025.
- Enlivex's Shares Outstanding (Entity) stood at $1.2 million in 2021, then climbed by 0.49% to $1.2 million in 2022, then climbed by 0.96% to $1.2 million in 2023, then rose by 27.17% to $1.6 million in 2024, then surged by 93.21% to $3.0 million in 2025.
- Business Quant data shows ENLV's Shares Outstanding (Entity) at $3.0 million in Q4 2025, $1.6 million in Q3 2025, and $1.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | 3.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.05 Mn |
| Sep 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 1.59 Mn |
| Mar 31, 2025 | 1.58 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.25 Mn |
| Dec 31, 2023 | 1.24 Mn |
| Sep 30, 2023 | 1.24 Mn |
| Jun 30, 2023 | 1.24 Mn |
| Mar 31, 2023 | 1.23 Mn |
| Dec 31, 2022 | 1.23 Mn |
| Sep 30, 2022 | 1.23 Mn |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | 1.22 Mn |
| Dec 31, 2021 | 1.19 Mn |
| Sep 30, 2021 | 1.22 Mn |
| Jun 30, 2021 | 1.22 Mn |
| Mar 31, 2021 | 1.10 Mn |